<DOC>
	<DOCNO>NCT01061359</DOCNO>
	<brief_summary>Evaluation efficacy treatment epirubicin ( 5 year follow-up ) . Evaluation frequency dose reduction . Evaluation frequency neoadjuvant treatment E ( 120mg ) / C ( 600mg ) . Evaluation unexpected serious adverse event . ( E=Epirubicin ; C =Cyclophosphamide )</brief_summary>
	<brief_title>Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer</brief_title>
	<detailed_description>Postmarketing surveillance study . Non-Probability Sample</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Pre postmenopausal female patient histologically confirm primary breast cancer Metastatic breast cancer , locally advanced recurrent breast cancer , previous cancer history</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Neoadjuvant Treatment</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Adjuvant</keyword>
	<keyword>Epirubicin</keyword>
</DOC>